跳至主要内容
临床试验/NCT01686009
NCT01686009已完成4 期

Intra-nasal Ketamine for Analgesia in the Emergency Department

Lions Gate Hospital1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2012年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
40
试验地点
1
主要终点
Proportion of subjects achieving a 13mm or more reduction in pain as measured on a 100-mm VAS within 30 minutes.

研究概览

简要总结

The provision of analgesia to patients in pain is a fundamental necessity of emergency department practice and is usually accomplished using IV opioids. However, significant barriers exist to the provision of timely analgesia by the IV route.

The use of the IN route for medication delivery provides an efficient and relatively painless mode of analgesia delivery. As well, ketamine is well-known to be an effective analgesic and to preserve cardiorespiratory function thus removing the necessity of physiologic monitoring that is obligatory when using opioids. The use of ketamine by the IN route provides a rapid, easy-administered and well-tolerated method for providing analgesia in the ED setting.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
6 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age 6 years or greater
  • moderate or severe pain (VAS >=50mm)

排除标准

  • history of allergy or intolerance to ketamine
  • structural or functional nasal occlusion
  • inability to understand the VAS
  • Glasgow Coma Scale < 15
  • Systolic BP > 180
  • History of schizophrenia
  • Clinical necessity for immediate IV access as judged by the treating physician

研究组 & 干预措施

Intra-nasal ketamine

Experimental

0.5 mg/kg ketamine intra-nasally; then 0.25 mg/kg repeat dose after 10 minutes if necessary

干预措施: Intra-nasal ketamine (Drug)

结局指标

主要结局

Proportion of subjects achieving a 13mm or more reduction in pain as measured on a 100-mm VAS within 30 minutes.

时间窗: 30 minutes

次要结局

  • Median maximum reduction in VAS pain score achieved within 30 minutes(30 minutes)
  • Median time required to achieve a 13-mm reduction in VAS pain score(1 hour)
  • Vital signs changes (ETCO2, O2sat, HR, RR, BP)(1 hour)
  • Adverse effects as defined by SERSDA(1 hour)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gary Andolfatto

Assistant Professor, University of British Columbia Department of Emergency Medicine; Attending Physician and Emergency Department Research Director, Lions Gate Hospital

Lions Gate Hospital

研究点 (1)

Loading locations...

相似试验

Intra-nasal Ketamine for Analgesia in the Emergency... | 临床试验